Please login to the form below

Not currently logged in
Email:
Password:

Pfizer may counter Daiichi's bid for Ranbaxy

Pfizer may be about to bid for a 65 per cent share of Indian generics company, Ranbaxy, according to a Business Standard report
Pfizer may be about to bid for a 65 per cent share of Indian generics company, Ranbaxy, according to a report in the Business Standard newspaper.

Ranbaxy, founded by the Singh family, has agreed a deal with Japan's Daiichi Sankyo, worth up to $4.6bn to take control of the company. However, it is rumoured that Pfizer, which held talks with Ranbaxy a year ago, may be about to make a counter bid.

According to the newspaper, a Ranbaxy spokesman said: "We have a binding contract with Daiichi. It is a final contract."

Pfizer has lost out to Ranbaxy in several international battles over the patent rights to Lipitor, its cholesterol drug. In most countries the patent will start expiring in 2011.

13th June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

It’s all about patient outcomes… right?
Lessons from history: a design thinking perspective...
Emma Walmsley 2
30 Women Leaders in UK Healthcare (part 3)
Continuing our special feature on Women Leaders in UK Healthcare...
Louise Houson
30 Women Leaders in UK Healthcare
The enormous challenges facing UK healthcare mean it needs great leaders. PME’s Group Editor Andrew McConaghie introduces 30 outstanding innovators and trailblazers helping to shape the future...

Infographics